ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Johnson & Johnson and Vanda Pharmaceuticals side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

Johnson & JohnsonVanda Pharmaceuticals
studies on the registry3,70982
open to participants now14616
phase 3 studies under way9512
reach primary completion within a year886
programswith a study of their own in two years56+4 named only9

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseJohnson & JohnsonVanda Pharmaceuticals
Phase 1

Johnson & Johnson: 26 of its 56 programs at phase 1

  1. Anti-CD79b/CD20/CD3 Trispecific Antibody JNJ-80948543phase 1
  2. Anti-PSMA Antibody-drug Conjugate ARX517phase 1
  3. JNJ-86974680phase 1
  4. JNJ-87801493phase 1
  5. JNJ-64264681phase 1

and 21 more — sign in to see them all

46%
00%
Phase 2

Johnson & Johnson: 8 of its 56 programs at phase 2

  1. JNJ-95597528phase 2
  2. anvatabart opadotinphase 2
  3. fludarabinephase 2
  4. JNJ-64042056phase 2
  5. JNJ-88545223phase 2

and 3 more — sign in to see them all

14%

Vanda Pharmaceuticals: 3 of its 9 programs at phase 2

  1. VSJ-110phase 2
  2. trichostatin Aphase 2
  3. VCA-894Aphase 2
33%
Phase 3

Johnson & Johnson: 18 of its 56 programs at phase 3

  1. amivantamabphase 3
  2. nipocalimabphase 3
  3. ramantamigphase 3
  4. icotrokinraphase 3
  5. lumateperonephase 3

and 13 more — sign in to see them all

32%

Vanda Pharmaceuticals: 4 of its 9 programs at phase 3

  1. tradipitantphase 3
  2. ponesimodphase 3
  3. milsaperidonephase 3
  4. VQW-765phase 3
44%
Approved, new studies

Johnson & Johnson: 4 of its 56 programs at approved, new studies

  1. guselkumabapproved, new study
  2. teclistamabapproved, new study
  3. ibrutinibapproved, new study
  4. Esketamineapproved, new study
7%

Vanda Pharmaceuticals: 2 of its 9 programs at approved, new studies

  1. tasimelteonapproved, new study
  2. iloperidoneapproved, new study
22%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
Johnson & Johnson26 readouts · 8 phase 3

Johnson & Johnson, Nov ’26: 1 program whose next study reaches primary completion

  1. JNJ-95597528phase 2 · Nov 19 · NCT07230860

Johnson & Johnson, Dec ’26: 9 programs whose next study reaches primary completion, 4 in phase 3

  1. anvatabart opadotinphase 2 · Dec 0 · NCT04829604
  2. milvexianphase 3 · Dec 8 · NCT05757869
  3. JNJ-89862175phase 1 · Dec 15 · NCT07223125
  4. nipocalimabphase 3 · Dec 15 · NCT05327114
  5. JNJ-64042056phase 2 · Dec 22 · NCT06544616

and 4 more — sign in to see them all

Johnson & Johnson, Jan ’27: 1 program whose next study reaches primary completion

  1. JNJ-86974680phase 1 · Jan 7 · NCT07319871

Johnson & Johnson, Feb ’27: 4 programs whose next study reaches primary completion, 3 in phase 3

  1. guselkumabapproved, new study · Feb 10 · NCT06260163
  2. icotrokinraphase 3 · Feb 10 · NCT06807424
  3. lazertinibphase 3 · Feb 12 · NCT04077463
  4. teclistamabapproved, new study · Feb 12 · NCT07030517

Johnson & Johnson, Mar ’27: 3 programs whose next study reaches primary completion

  1. Anti-ENPP3/Anti-CD3 Bispecific Antibody JNJ-87890387phase 1 · Mar 16 · NCT06178614
  2. deulumateperonephase 3 · Mar 16 · NCT06480383
  3. pasritamigphase 3 · Mar 31 · NCT04898634

Johnson & Johnson, Apr ’27: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. lumateperonephase 3 · Apr 5 · NCT05850689
  2. ramantamigphase 3 · Apr 19 · NCT05652335
·

Johnson & Johnson, Jun ’27: 4 programs whose next study reaches primary completion

  1. Anti-CALRmut/Anti-CD3 Bispecific Antibody JNJ-88549968phase 1 · Jun 14 · NCT06150157
  2. Anti-PSMA/Anti-CD28 Bispecific Antibody JNJ-87189401phase 3 · Jun 21 · NCT06095089
  3. Aticaprantphase 3 · Jun 21 · NCT07615426
  4. JNJ-88545223phase 2 · Jun 28 · NCT07321873
·

Johnson & Johnson, Aug ’27: 1 program whose next study reaches primary completion

  1. JNJ-90189892phase 1 · Aug 5 · NCT06651229
·

Johnson & Johnson, Oct ’27: 1 program whose next study reaches primary completion

  1. JNJ-88998377phase 1 · Oct 29 · NCT06470438
Vanda Pharmaceuticals3 readouts · 2 phase 3·

Vanda Pharmaceuticals, Dec ’26: 2 programs whose next study reaches primary completion, 2 in phase 3

  1. VQW-765phase 3 · Dec 0 · NCT07221578
  2. tradipitantphase 3 · Dec 1 · NCT07446439
··

Vanda Pharmaceuticals, Mar ’27: 1 program whose next study reaches primary completion

  1. VCA-894Aphase 2 · Mar 0 · NCT07223632
·······
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 20, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

Johnson & Johnson

New programs 1

Reached a new phase 2

Study stopped 0

None

Primary completion later 3

Vanda Pharmaceuticals

New programs 0

None

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 1

Where they overlap

Conditions where at least two of them have programs: 8 in all. A program counts in each condition its studies name most.

ConditionJohnson & JohnsonVanda Pharmaceuticals
Depressive Disorder, Majorboth · compare here

Johnson & Johnson in Depressive Disorder, Major: 5 programs

  1. lumateperonephase 3
  2. seltorexantphase 3
  3. Aticaprantphase 3
  4. JNJ-89495120phase 2
  5. Esketamineapproved, new study

Their studies: Johnson & Johnson’s studies of Depressive Disorder, Major in search

Vanda Pharmaceuticals in Depressive Disorder, Major: 2 programs

  1. milsaperidonephase 3
  2. tasimelteonapproved, new study

Their studies: Vanda Pharmaceuticals’ studies of Depressive Disorder, Major in search

Colitis, Ulcerativeboth · compare here

Johnson & Johnson in Colitis, Ulcerative: 4 programs

  1. icotrokinraphase 3
  2. JNJ-78934804phase 3
  3. risankizumabphase 3
  4. guselkumabapproved, new study

Their studies: Johnson & Johnson’s studies of Colitis, Ulcerative in search

Vanda Pharmaceuticals in Colitis, Ulcerative: 1 program

  1. ponesimodphase 3

Their studies: Vanda Pharmaceuticals’ studies of Colitis, Ulcerative in search

Psoriasisboth · compare here

Johnson & Johnson in Psoriasis: 3 programs

  1. icotrokinraphase 3
  2. risankizumabphase 3
  3. guselkumabapproved, new study

Their studies: Johnson & Johnson’s studies of Psoriasis in search

Vanda Pharmaceuticals in Psoriasis: 1 program

  1. ponesimodphase 3

Their studies: Vanda Pharmaceuticals’ studies of Psoriasis in search

Schizophreniaboth · compare here

Johnson & Johnson in Schizophrenia: 2 programs

  1. lumateperonephase 3
  2. Aticaprantphase 3

Their studies: Johnson & Johnson’s studies of Schizophrenia in search

Vanda Pharmaceuticals in Schizophrenia: 2 programs

  1. milsaperidonephase 3
  2. iloperidoneapproved, new study

Their studies: Vanda Pharmaceuticals’ studies of Schizophrenia in search

Dermatitis, Atopicboth · compare here

Johnson & Johnson in Dermatitis, Atopic: 2 programs

  1. JNJ-95597528phase 2
  2. JNJ-95475939phase 2

Their studies: Johnson & Johnson’s studies of Dermatitis, Atopic in search

Vanda Pharmaceuticals in Dermatitis, Atopic: 1 program

  1. tradipitantphase 3

Their studies: Vanda Pharmaceuticals’ studies of Dermatitis, Atopic in search

Renal Insufficiencyboth · compare here

Johnson & Johnson in Renal Insufficiency: 2 programs

  1. seltorexantphase 3
  2. olomorasibphase 2

Their studies: Johnson & Johnson’s studies of Renal Insufficiency in search

Vanda Pharmaceuticals in Renal Insufficiency: 1 program

  1. tasimelteonapproved, new study

Their studies: Vanda Pharmaceuticals’ studies of Renal Insufficiency in search

Hematologic Neoplasmsboth · compare here

Johnson & Johnson in Hematologic Neoplasms: 1 program

  1. teclistamabapproved, new study

Their studies: Johnson & Johnson’s studies of Hematologic Neoplasms in search

Vanda Pharmaceuticals in Hematologic Neoplasms: 1 program

  1. trichostatin Aphase 2

Their studies: Vanda Pharmaceuticals’ studies of Hematologic Neoplasms in search

Sleep Initiation and Maintenance Disordersboth · compare here

Johnson & Johnson in Sleep Initiation and Maintenance Disorders: 1 program

  1. seltorexantphase 3

Their studies: Johnson & Johnson’s studies of Sleep Initiation and Maintenance Disorders in search

Vanda Pharmaceuticals in Sleep Initiation and Maintenance Disorders: 1 program

  1. tasimelteonapproved, new study

Their studies: Vanda Pharmaceuticals’ studies of Sleep Initiation and Maintenance Disorders in search

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

TargetJohnson & JohnsonVanda Pharmaceuticals
DRD2lumateperoneruleiloperidonerule
HTR2Alumateperoneruleiloperidonerule
A target, or a pathogen for a vaccine, known for: Johnson & Johnson 33 of 56 · Vanda Pharmaceuticals 4 of 9 programs (22 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.
  • Programs a company names but has not registered are counted apart (Johnson & Johnson: 4).